These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 12569967)

  • 1. Treatment of spasticity with botulinum toxin.
    O'Brien CF
    Clin J Pain; 2002; 18(6 Suppl):S182-90. PubMed ID: 12569967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of botulinum toxin type A and type B for spasticity in upper and lower limbs.
    Bell KR; Williams F
    Phys Med Rehabil Clin N Am; 2003 Nov; 14(4):821-35. PubMed ID: 14580040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin and spasticity.
    Davis EC; Barnes MP
    J Neurol Neurosurg Psychiatry; 2000 Aug; 69(2):143-7. PubMed ID: 10896682
    [No Abstract]   [Full Text] [Related]  

  • 4. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin.
    Koman LA; Paterson Smith B; Balkrishnan R
    Paediatr Drugs; 2003; 5(1):11-23. PubMed ID: 12513103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Spasticity and botulinum toxin in 2003. An update].
    Fève A
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):265-70. PubMed ID: 12746701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum neurotoxin intramuscular chemodenervation. Role in the management of spastic hypertonia and related motor disorders.
    Yablon SA
    Phys Med Rehabil Clin N Am; 2001 Nov; 12(4):833-74, vii-viii. PubMed ID: 11723867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasonographic evaluation of changes in the muscle architecture of the gastrocnemius with botulinum toxin treatment for lower extremity spasticity in children with cerebral palsy.
    Kawano A; Yanagizono T; Kadouchi I; Umezaki T; Chosa E
    J Orthop Sci; 2018 Mar; 23(2):389-393. PubMed ID: 29146092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity.
    Yang TF; Fu CP; Kao NT; Chan RC; Chen SJ
    Am J Phys Med Rehabil; 2003 Apr; 82(4):284-9. PubMed ID: 12649654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spinal cord injury and use of botulinum toxin in reducing spasticity.
    Fried GW; Fried KM
    Phys Med Rehabil Clin N Am; 2003 Nov; 14(4):901-10. PubMed ID: 14580044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with botulinum toxin in children with cerebral palsy: a qualitative study of parents' experiences.
    Lorin K; Forsberg A
    Child Care Health Dev; 2016 Jul; 42(4):494-503. PubMed ID: 27198886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum Toxin A Injection in Treatment of Upper Limb Spasticity in Children with Cerebral Palsy: A Systematic Review of Randomized Controlled Trials.
    Farag SM; Mohammed MO; El-Sobky TA; ElKadery NA; ElZohiery AK
    JBJS Rev; 2020 Mar; 8(3):e0119. PubMed ID: 32224633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the functional outcomes of ultrasound-guided botulinum toxin type A injections using the Euro-musculus approach for upper limb spasticity treatment in post-stroke patients: an observational study.
    Buyukavci R; Akturk S; Ersoy Y
    Eur J Phys Rehabil Med; 2018 Oct; 54(5):738-744. PubMed ID: 29422486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upper extremity spasticity in children with cerebral palsy: a randomized, double-blind, placebo-controlled study of the short-term outcomes of treatment with botulinum A toxin.
    Koman LA; Smith BP; Williams R; Richardson R; Naughton M; Griffin L; Evans P
    J Hand Surg Am; 2013 Mar; 38(3):435-46.e1. PubMed ID: 23428186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of neural lesion type on botulinum toxin dosage: a retrospective chart review.
    Phadke CP; Davidson C; Ismail F; Boulias C
    PM R; 2014 May; 6(5):406-11. PubMed ID: 24211697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity.
    Santamato A; Panza F
    Drugs; 2017 Sep; 77(13):1413-1422. PubMed ID: 28726023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type A for upper limb spasticity after stroke.
    Shaw L; Rodgers H
    Expert Rev Neurother; 2009 Dec; 9(12):1713-25. PubMed ID: 19951131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment with botulinum toxin in neurologic pediatrics].
    Justus N; Lee SH; Berweck S; Heinen F
    Kinderkrankenschwester; 2007 Jul; 26(7):274-6. PubMed ID: 17726921
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of spasticity in children with cerebral palsy with botulinum toxin A].
    Madsen ES; Sonne-Holm S; Wong C; Curtis D; Bencke J
    Ugeskr Laeger; 2015 Jan; 177(3):V07140409. PubMed ID: 25613095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection.
    Hurvitz EA; Conti GE; Brown SH
    Arch Phys Med Rehabil; 2003 Mar; 84(3):444-54. PubMed ID: 12638115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.